ArticleEuropean journal of medical research2025
Plasma untargeted metabolomics reveals the metabolic landscape of NKTCL and aids in liquid biopsy for disease detection.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic reprogramming is a significant hallmark of NK/T-cell lymphoma (NKTCL). A comprehensive analysis of the alterations in the metabolic landscape of NKTCL is crucial for facilitating early non-invasive screening and providing new therapeutic strategies.
methodsIn this study, we employed a non-targeted approach using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to analyze the plasma of 92 NKTCL patients and 28 healthy controls, comparing the metabolic profiles of both groups.
resultsWe found significant differences in the plasma metabolic landscape between NKTCL patients and healthy individuals. The differential metabolites were primarily enriched in purine metabolism, arginine and proline metabolism, pyrimidine metabolism, and arginine biosynthesis pathways. Three of these metabolites were used to construct a diagnostic model, demonstrating good diagnostic and therapeutic efficacy.
conclusionsUtilizing LC-HRMS for non-targeted metabolomics can aid in the early screening of NKTCL and provide new therapeutic insights and theoretical foundations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.